Eliezer M Van Allen1, Todd Miyake, Nathan Gunn, Caroline M Behler, Jeff Kohlwes. 1. Department of Biology and Department of Economics, University of California, San Diego; Verisk Health, Waltham, MA; Department of Medicine, Department of Hematology/Oncology, and PRIME Residency Program, San Francisco Veterans Affairs Medical Center, San Francisco, CA; Department of Medicine, and Department of Malignant Hematology and Bone Marrow Transplant, University of California, San Francisco.
Abstract
PURPOSE: Off-label prescribing in oncology is common and unregulated. The aim of this study was to describe the off-label use of rituximab, a novel anti-CD20 antibody, among patients from a large proprietary insurance database to understand how frequently and appropriately off-label prescribing occurs for this medication. PATIENTS AND METHODS: In this descriptive study, 11,232,642 patients were enrolled in the D2 Hawkeye commercial insurance database between 2001 and 2007, and 2,782 patients received rituximab. The main outcome measures were quantity and type of off-label usage, and expenditures for off-label usage. RESULTS: Seven hundred five (25.3%) patients received rituximab for off-label indications, and of those, 332 (47.1%) received rituximab for uncertain or inadequate evidence-based diagnoses. Expenditures for off-label indications were 17.1% of expenditures for rituximab usage. CONCLUSION: The frequent use of rituximab for off-label indications should lead to improved postapproval surveillance of biologics by the US Food and Drug Administration, so that use can be adequately studied. This will also facilitate improved regulatory mechanisms to ensure evidence-based use.
PURPOSE: Off-label prescribing in oncology is common and unregulated. The aim of this study was to describe the off-label use of rituximab, a novel anti-CD20 antibody, among patients from a large proprietary insurance database to understand how frequently and appropriately off-label prescribing occurs for this medication. PATIENTS AND METHODS: In this descriptive study, 11,232,642 patients were enrolled in the D2 Hawkeye commercial insurance database between 2001 and 2007, and 2,782 patients received rituximab. The main outcome measures were quantity and type of off-label usage, and expenditures for off-label usage. RESULTS: Seven hundred five (25.3%) patients received rituximab for off-label indications, and of those, 332 (47.1%) received rituximab for uncertain or inadequate evidence-based diagnoses. Expenditures for off-label indications were 17.1% of expenditures for rituximab usage. CONCLUSION: The frequent use of rituximab for off-label indications should lead to improved postapproval surveillance of biologics by the US Food and Drug Administration, so that use can be adequately studied. This will also facilitate improved regulatory mechanisms to ensure evidence-based use.
Authors: J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith Journal: Ann Neurol Date: 2009-10 Impact factor: 10.422
Authors: Holger Schulz; Ute Rehwald; Franck Morschhauser; Thomas Elter; Christoph Driessen; Thomas Rüdiger; Peter Borchmann; Roland Schnell; Volker Diehl; Andreas Engert; Marcel Reiser Journal: Blood Date: 2007-10-15 Impact factor: 22.113
Authors: Rena M Conti; Arielle C Bernstein; Victoria M Villaflor; Richard L Schilsky; Meredith B Rosenthal; Peter B Bach Journal: J Clin Oncol Date: 2013-02-19 Impact factor: 44.544
Authors: Joseph M Unger; Dawn L Hershman; Diane Martin; Ruth B Etzioni; William E Barlow; Michael LeBlanc; Scott R Ramsey Journal: J Natl Cancer Inst Date: 2014-12-24 Impact factor: 13.506
Authors: I Danés; A Agustí; A Vallano; J Martínez; C Alerany; A Ferrer; A López; J Cortés-Hernández; J A Bosch Journal: Eur J Clin Pharmacol Date: 2013-05-23 Impact factor: 2.953